Latest & greatest articles for nsaids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nsaids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nsaids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nsaids

121. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis

Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis Scheiman J M, Bandekar R R, Chernew M E, Fendrick A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of Helicobacter pylori (Hp) screening for chronic users of non-steroidal anti-inflammatory drugs (NSAIDs). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population included all NSAID users at an average risk of peptic ulcer disease. More detailed characteristics

2001 NHS Economic Evaluation Database.

122. Prevention of chronic NSAID induced upper gastrointestinal toxicity. (PubMed)

Prevention of chronic NSAID induced upper gastrointestinal toxicity. Non-steroidal anti-inflammatory drugs (NSAIDs) are important agents in the management of arthritic and inflammatory conditions, and are among the most frequently prescribed medications in North America and Europe. However, there is overwhelming evidence linking these agents to a variety of gastrointestinal (GI) toxicities.To review the effectiveness of common interventions for the prevention of NSAID induced upper GI (...) analogues (PA), H2-receptor antagonists (H2RA) or proton pump inhibitors (PPI) for the prevention of chronic NSAID induced upper GI toxicity were included.Two independent reviewers extracted data regarding population characteristics, study design, methodological quality and number of patients with endoscopic ulcers, ulcer complications, symptoms, overall drop-outs, drop outs due to symptoms. Dichotomous data was pooled using Revman V3.1. Heterogeneity was evaluated using a chi square test.Thirty-three

2000 Cochrane

123. Prevention of NSAID-induced gastroduodenal ulcers. (PubMed)

Prevention of NSAID-induced gastroduodenal ulcers. Non-steroidal anti-inflammatory drugs (NSAIDs) are important agents in the management of arthritic and inflammatory conditions, and are among the most frequently prescribed medications in North America and Europe. However, there is overwhelming evidence linking these agents to a variety of gastrointestinal (GI) toxicities.To review the effectiveness of common interventions for the prevention of NSAID induced upper GI toxicity.A literature (...) ), H2-receptor antagonists (H2RA) or proton pump inhibitors (PPI) for the prevention of chronic NSAID induced upper GI toxicity were included.Two independent reviewers extracted data regarding population characteristics, study design, methodological quality and number of patients with endoscopic ulcers, ulcer complications, symptoms, overall drop-outs, drop outs due to symptoms. Dichotomous data was pooled using Revman V3.1. Heterogeneity was evaluated using a chi square test.Thirty-three RCTs met

2000 Cochrane

124. Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action

Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Local infiltration with NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action Romsing J, Moiniche S, Ostergaard D, Dahl JB Authors' objectives To investigate the evidence for a peripheral analgesic effect of local infiltration with non-steroidal anti-inflammatory (...) drugs (NSAIDs) in post-operative pain. Searching MEDLINE was searched from 1966 to September 1999, EMBASE from 1989 to August 1999, and the Cochrane library in 1999, using the search terms 'NSAID', 'non-steroidal anti-inflammatory drug', individual drug names, 'postoperative pain', 'local infiltration', 'intra-articular', 'regional' and 'surgical site'. There were no restrictions on publication language. Additional studies were identified from the references lists of retrieved reports. Abstracts

2000 DARE.

125. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Tramer M R, Moore R A, Reynolds D J, McQuay H J Authors' objectives To estimate the incidence of death from (...) gastroduodenal complications with chronic use of non-steroidal anti-inflammatory drugs (NSAIDs). Searching MEDLINE and EMBASE (up to December 1996) were searched for articles published in any language, using the following free text terms either alone or in combination: 'non-steroidal anti-inflammatory drug', 'aspirin', 'ulcer', 'bleeding', 'haemorrhage', 'perforation' and 'death'. Additional studies were identified by handsearching reference lists from retrieved reports, review articles on NSAIDs, relevant

2000 DARE.

126. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. (PubMed)

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) toxic effects, such as upper GI tract perforations, symptomatic gastroduodenal ulcers, and upper GI tract bleeding (PUBs), are thought to be attributable to cyclooxygenase 1 (COX-1) inhibition. Rofecoxib specifically inhibits COX-2 and has demonstrated a low potential for causing upper GI injury.To compare the incidence of PUBs in patients (...) ; mean age, 63 years [range, 38-94 years]; 72.9% women).Rofecoxib, 12.5, 25, or 50 mg/d (n = 1209, 1603, and 545, respectively, combined) vs ibuprofen, 800 mg 3 times per day (n = 847), diclofenac, 50 mg 3 times per day (n = 590); or nabumetone, 1500 mg/d (n = 127) (combined).Cumulative incidence of PUBs for rofecoxib vs NSAIDs, based on survival analysis of time to first PUB diagnosis, using PUBs that met pre-specified criteria judged by a blinded, external adjudication committee.The incidence

1999 JAMA

127. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. (PubMed)

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. Suppressing acid secretion is thought o reduce the risk of ulcers associated with regular use of nonsteroidal antiinflammatory drugs (NSAIDs), but the best means of accomplishing this is uncertain.We studied 541 patients who required continuous treatment with NSAIDs and who (...) of omeprazole). The rates of healing of all types of lesions were higher with omeprazole than with ranitidine. During maintenance therapy, the estimated proportion of patients in remission at the end of six months was 72 percent in the omeprazole group and 59 percent in the ranitidine group. The rates of adverse events were similar between groups during both phases. Both medications were well tolerated.In patients with regular use of NSAIDs, omeprazole healed and prevented ulcers more effectively than did

1998 NEJM

128. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. (PubMed)

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Misoprostol is effective for ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) but is often poorly tolerated because of diarrhea and abdominal pain. We compared the efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs.In a double-blind (...) study, we randomly assigned 935 patients who required continuous NSAID therapy and who had ulcers or more than 10 erosions in the stomach or duodenum (or both) to receive 20 mg or 40 mg of omeprazole orally in the morning or 200 microg of misoprostol orally four times daily. Patients were treated for four weeks or, in the absence of healing, eight weeks. Treatment success was defined as the absence of ulcers and the presence of fewer than five erosions at each site and not more than mild dyspepsia

1998 NEJM

129. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. (PubMed)

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. The effect of Helicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) is unclear. We investigated the effects of H. pylori eradication in patients with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs.285 patients were randomly assigned (...) omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily (n=142, H. pylori eradication treatment), or omeprazole with placebo antibiotics (n=143, controls) for 1 week. All patients received omeprazole 20 mg once daily for 3 weeks until endoscopy, and, if the ulcer was not healed, 40 mg once daily until repeat endoscopy at 8 weeks. Ulcer-free patients with mild dyspepsia continued NSAIDs but not antiulcer treatment. We investigated ulcers with endoscopy at 1, 3, and 6 months

1998 Lancet

130. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK

Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK McCabe C J, Akehurst R L, Kirsch J, Whitfield M, Backhouse M, Woolf A D, Scott D L, Emery P, Haslock I Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Non-steroidal anti-inflammatory drugs (NSAIDs) for the management of rheumatoid arthritis and osteoarthritis: nabumetone (between 1,000 and 2,000 mg per day), diclofenac (100-200 mg per day), ibuprofen (1,200

1998 NHS Economic Evaluation Database.

131. Meta-analysis of risk of gastrointestinal complications with NSAIDs. Narrative review should have been used. (PubMed)

Meta-analysis of risk of gastrointestinal complications with NSAIDs. Narrative review should have been used. 9040416 1997 03 31 2008 11 20 0959-8138 314 7078 1997 Feb 08 BMJ (Clinical research ed.) BMJ Meta-analysis of risk of gastrointestinal complications with NSAIDs. Narrative review should have been used. 445-6 Kaufman D W DW Shapiro S S eng Comment Letter England BMJ 8900488 0959-8138 0 Anti-Inflammatory Agents, Non-Steroidal AIM IM BMJ. 1996 Jun 22;312(7046):1563-6 8664664 BMJ. 1997 Jun

Full Text available with Trip Pro

1997 BMJ

132. Meta-analysis of risk of gastrointestinal complications with NSAIDs. Authors should not have included data from one study. (PubMed)

Meta-analysis of risk of gastrointestinal complications with NSAIDs. Authors should not have included data from one study. 9040415 1997 03 31 2008 11 20 0959-8138 314 7078 1997 Feb 08 BMJ (Clinical research ed.) BMJ Meta-analysis of risk of gastrointestinal complications with NSAIDs. Authors should not have included data from one study. 445 Henry D D eng Comment Letter England BMJ 8900488 0959-8138 0 Anti-Inflammatory Agents, Non-Steroidal AIM IM BMJ. 1996 Jun 22;312(7046):1563-6 8664664 Anti

Full Text available with Trip Pro

1997 BMJ

133. [Cost-effectiveness of misoprostol administration in the prevention of NSAID-induced gastric ulcer]

[Cost-effectiveness of misoprostol administration in the prevention of NSAID-induced gastric ulcer] Die Kosten-Effektivitat der Misoprostoltherapie in der Pravention NSAR-induzierter Magenulzera [Cost-effectiveness of misoprostol administration in the prevention of NSAID-induced gastric ulcer] Die Kosten-Effektivitat der Misoprostoltherapie in der Pravention NSAR-induzierter Magenulzera [Cost-effectiveness of misoprostol administration in the prevention of NSAID-induced gastric ulcer] Schwarz B (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The administration of misoprostol, a prostaglandin E analog, to patients already taking non-steroidal anti-inflammatory drugs (NSAID) in order to prevent the incidence of gastric

1995 NHS Economic Evaluation Database.

134. The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints: a systematic review

The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints: a systematic review The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints: a systematic review The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints: a systematic review van der Windt D A, van der Heijden G J, Scholten R J, Koes B W, Bouter L M Authors' objectives To examine the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs (...) designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review NSAIDs, either compared to placebo or to other treatment modalities, or to another NSAID. A variety of drugs were studied including naproxen, diclofenac and flurbiprofen. Participants included in the review At least 90% of the study population had to be patients with intrinsic shoulder complaints which included bursitis, tendinitis, periarthritis and capsulitis

1995 DARE.

135. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. (PubMed)

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. A double-blind, placebo-controlled study was carried out to see whether the synthetic E prostaglandin, misoprostol, would prevent gastric ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs). 420 patients with osteoarthritis and NSAID-associated abdominal pain were studied; they were receiving ibuprofen, piroxicam, or naproxen. Endoscopy was done at entry and after 1, 2 (...) , and 3 months of continuous treatment with 100 micrograms or 200 micrograms misoprostol or placebo, given four times daily with meals and at bedtime, concurrently with the NSAID. Abdominal pain was rated independently by patients and physicians. A treatment failure was defined as development of a gastric ulcer. Gastric ulcers (0.3 cm in diameter or greater) occurred less frequently (p less than 0.001) in both misoprostol treatment groups (5.6% 100 micrograms and 1.4% 200 micrograms) than

1988 Lancet